The financials
Recursion Pharmaceuticals, Inc. by the numbers
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $6.5M in Q1 2026 (quarter ended Mar 31, 2026), down 56% from the same quarter a year earlier. That came with a gross margin of −93% and net loss of $118M. For the full year FY2025, revenue was $75M (+27% year on year) and net income −$645M. Its largest product in Jun 2026 was License And Service at $7.3M, 95% of the disclosed total, well ahead of Grant at 4.8%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $6.5M | $15M | −56% |
| Gross profit | −$6.0M | −$7.1M | n/a |
| Operating income | −$129M | −$191M | n/a |
| Net income | −$118M | −$202M | n/a |
| Diluted EPS | −$0.22 | −$0.50 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Service | $7.3M | 95% |
| Grant | $367K | 4.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $7.7M (+19%)
Grant grew +206% year on yearLicense And Service -62% year on year
Segment Latestquarter on quarteryear on year
- License And Service$7.3M$7.3MQoQ +16%year on year -62%+16%-62%
- Grant$367.0K$367.0KQoQ +115%year on year +206%+115%+206%